Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects
Abstract
Share and Cite
Kowalczyk, A.; Zarychta, J.; Lejman, M.; Latoch, E.; Zawitkowska, J. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects. Int. J. Mol. Sci. 2024, 25, 7916. https://doi.org/10.3390/ijms25147916
Kowalczyk A, Zarychta J, Lejman M, Latoch E, Zawitkowska J. Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects. International Journal of Molecular Sciences. 2024; 25(14):7916. https://doi.org/10.3390/ijms25147916
Chicago/Turabian StyleKowalczyk, Adrian, Julia Zarychta, Monika Lejman, Eryk Latoch, and Joanna Zawitkowska. 2024. "Clinical Implications of Isocitrate Dehydrogenase Mutations and Targeted Treatment of Acute Myeloid Leukemia with Mutant Isocitrate Dehydrogenase Inhibitors—Recent Advances, Challenges and Future Prospects" International Journal of Molecular Sciences 25, no. 14: 7916. https://doi.org/10.3390/ijms25147916